BRPI0518904A2 - formulaÇÕes de nepafenac tàpicas - Google Patents

formulaÇÕes de nepafenac tàpicas

Info

Publication number
BRPI0518904A2
BRPI0518904A2 BRPI0518904-7A BRPI0518904A BRPI0518904A2 BR PI0518904 A2 BRPI0518904 A2 BR PI0518904A2 BR PI0518904 A BRPI0518904 A BR PI0518904A BR PI0518904 A2 BRPI0518904 A2 BR PI0518904A2
Authority
BR
Brazil
Prior art keywords
typical
nepafenac
formulations
nepafenac formulations
compositions
Prior art date
Application number
BRPI0518904-7A
Other languages
English (en)
Inventor
Warren Wong
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518904(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0518904A2 publication Critical patent/BRPI0518904A2/pt
Publication of BRPI0518904B1 publication Critical patent/BRPI0518904B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAÇÕES DE NEPAFENAC TàPICAS. A presente invenção refere-se a composições em suspensão tópicas de nepafenac são descritas. As composições são especialmente adequadas para administração oftálmica tópica.
BRPI0518904-7A 2004-12-02 2005-12-02 Composições oftálmicas topicamente administráveis BRPI0518904B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63256204P 2004-12-02 2004-12-02
US60/632,562 2004-12-02
PCT/US2005/043545 WO2006060618A2 (en) 2004-12-02 2005-12-02 Topical nepafenac formulations

Publications (2)

Publication Number Publication Date
BRPI0518904A2 true BRPI0518904A2 (pt) 2008-12-16
BRPI0518904B1 BRPI0518904B1 (pt) 2023-01-24

Family

ID=35848959

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518904-7A BRPI0518904B1 (pt) 2004-12-02 2005-12-02 Composições oftálmicas topicamente administráveis

Country Status (24)

Country Link
US (3) US7834059B2 (pt)
EP (1) EP1819362B1 (pt)
JP (2) JP4968844B2 (pt)
KR (1) KR101289661B1 (pt)
CN (1) CN101068573A (pt)
AR (1) AR052252A1 (pt)
AT (1) ATE476200T1 (pt)
AU (1) AU2005311738B2 (pt)
BR (1) BRPI0518904B1 (pt)
CA (1) CA2586807C (pt)
CY (1) CY1110780T1 (pt)
DE (1) DE602005022756D1 (pt)
DK (1) DK1819362T3 (pt)
ES (1) ES2348249T3 (pt)
HK (1) HK1104225A1 (pt)
MX (1) MX2007006558A (pt)
PL (1) PL1819362T3 (pt)
PT (1) PT1819362E (pt)
RU (1) RU2007124638A (pt)
SI (1) SI1819362T1 (pt)
TW (1) TWI358290B (pt)
UY (1) UY29238A1 (pt)
WO (1) WO2006060618A2 (pt)
ZA (1) ZA200704763B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
AU2006244244B2 (en) * 2005-05-10 2010-11-04 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
WO2008153746A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
TWI531362B (zh) * 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP5583145B2 (ja) * 2009-03-03 2014-09-03 アルコン リサーチ， リミテッド レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
BR112012013503B8 (pt) 2009-12-03 2021-05-25 Alcon Res Llc composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
JP6150079B2 (ja) * 2011-12-16 2017-06-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ポリビニルカプロラクタム−ポリビニルアセテート−ポリエチレングリコールグラフト共重合体を含む眼用組成物
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
ES2966595T3 (es) 2015-01-26 2024-04-23 Bausch & Lomb Composición de suspensión oftálmica
US9930060B2 (en) 2015-06-01 2018-03-27 Duo Security, Inc. Method for enforcing endpoint health standards
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (pt) 1967-07-31 1971-03-24
CH577461A5 (pt) 1975-08-13 1976-07-15 Robins Co Inc A H
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
EP0195582B1 (en) 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
PL373787A1 (en) 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations

Also Published As

Publication number Publication date
EP1819362A2 (en) 2007-08-22
ZA200704763B (en) 2008-09-25
ES2348249T3 (es) 2010-12-02
AR052252A1 (es) 2007-03-07
DK1819362T3 (da) 2010-10-18
WO2006060618A2 (en) 2006-06-08
ATE476200T1 (de) 2010-08-15
EP1819362B1 (en) 2010-08-04
CN101068573A (zh) 2007-11-07
JP2012041368A (ja) 2012-03-01
CA2586807C (en) 2013-01-29
TWI358290B (en) 2012-02-21
SI1819362T1 (sl) 2010-10-29
KR101289661B1 (ko) 2013-07-29
RU2007124638A (ru) 2009-01-10
AU2005311738B2 (en) 2011-02-03
UY29238A1 (es) 2006-05-31
US7834059B2 (en) 2010-11-16
KR20070089687A (ko) 2007-08-31
DE602005022756D1 (de) 2010-09-16
US20110015271A1 (en) 2011-01-20
CA2586807A1 (en) 2006-06-08
US8071648B2 (en) 2011-12-06
US8324281B2 (en) 2012-12-04
PL1819362T3 (pl) 2010-12-31
AU2005311738A1 (en) 2006-06-08
TW200626132A (en) 2006-08-01
JP2008521926A (ja) 2008-06-26
JP4968844B2 (ja) 2012-07-04
WO2006060618A3 (en) 2006-10-19
US20060122277A1 (en) 2006-06-08
HK1104225A1 (en) 2008-01-11
MX2007006558A (es) 2007-06-15
US20120029084A1 (en) 2012-02-02
PT1819362E (pt) 2010-10-11
CY1110780T1 (el) 2015-06-10
BRPI0518904B1 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
BRPI0509184A (pt) composições farmacêuticas
NO20090175L (no) Stabile laquinimod sammensetninger
WO2009111653A3 (en) Antiviral therapeutic agents
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
ECSP088717A (es) Derivados de amina
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
NO20091395L (no) Nye tiofenderivater
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
GT200600117A (es) Nuevos compuestos farmaceuticos
EA201170703A1 (ru) Производные адамантилбензамида
TW200942524A (en) Novel aminomethyl benzene derivatives
NO20043367L (no) Oralt farmasoytisk preparat
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
BRPI0920355B8 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
WO2011006935A3 (en) Tetrazole derivatives
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.